Wegovy

News

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

Novo Nordisk has moved quickly to file for approval of a higher-dose version of obesity drug Wegovy as it fends off stiff competition from Eli Lilly.

News

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

News

The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.

News

Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.

News

Combining weight-loss drugs with online patient support can achieve results that match the drugs given on their own, but with a much-reduced dose.